Inmune Bio, Inc. 8-K Filing
Ticker: INMB · Form: 8-K · Filed: Dec 5, 2025 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Dec 5, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Inmune Bio, Inc. (ticker: INMB) to the SEC on Dec 5, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma).
How long is this filing?
Inmune Bio, Inc.'s 8-K filing is 2 pages with approximately 499 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 499 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-12-05 16:00:39
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
Filing Documents
- ea0268534-8k_inmune.htm (8-K) — 24KB
- ea026853401ex99-1_inmune.htm (EX-99.1) — 16KB
- ea026853401ex99-2_inmune.htm (EX-99.2) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- ex99-2_001.jpg (GRAPHIC) — 2KB
- 0001213900-25-118699.txt ( ) — 235KB
- inmb-20251201.xsd (EX-101.SCH) — 3KB
- inmb-20251201_lab.xml (EX-101.LAB) — 33KB
- inmb-20251201_pre.xml (EX-101.PRE) — 22KB
- ea0268534-8k_inmune_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On December 1, 2025, INmune Bio Inc. (the "Company") issued a press release announcing new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in patients with early Alzheimer's disease and elevated neuroinflammation. A copy of the press release is attached herewith as Exhibit 99.1 and is incorporated herein by reference. On December 5, 2025, the Company issued a press release announcing a recently published overview of future applications and research areas for mesenchymal stromal cell therapies, such as the Company's CORDStrom platform. A copy of the press release is attached as Exhibit 99.2 and is incorporated herein by reference.
01 Financial statements and Exhibits
Item 9.01 Financial statements and Exhibits (d) Exhibits. 99.1 Press Release, dated December 1, 2025 99.2 Press Release, dated December 5, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: December 5, 2025 By: /s/ David Moss David Moss Chief Executive Officer 2